Records containing: Malignant Melanoma

This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.

All FDA submission records EMA medicine records ClinicalTrials.gov record updates ClinicalTrials.gov records with results posted

CLINICAL_TRIALS study record update · 2017-05-15
A Phase 2 Study of the Efficacy and Safety of Intratumoral CAVATAK™ (Coxsackievirus A21, CVA21) in Patients With Stage IIIc and Stage IV Malignant Melanoma (VLA-007 CALM )
CLINICAL_TRIALS study record update · 2017-05-03
An Open-label, Uncontrolled, Single Arm Phase II Trial of Buparlisib in Patients With Metastatic Melanoma With Brain Metastases Not Eligible for Surgery or Radiosurgery
CLINICAL_TRIALS study record update · 2017-04-21
Phase II Study of Dacarbazine With the Anti-Vascular Endothelial Growth Factor Antibody (Bevacizumab) in Patients With Unresectable/Metastatic Melanoma
CLINICAL_TRIALS study record update · 2017-04-19
A Phase II Study of Vemurafenib Combined With Acitretin in Patients With Advanced Melanoma
CLINICAL_TRIALS study record update · 2017-03-28
A Pilot/Phase I Study of Panobinostat (LBH589) in Patients With Metastatic Melanoma
Organize your saved records without ads with Plus.
CLINICAL_TRIALS study record update · 2017-03-28
Randomized, Phase II Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Patients With Advanced Melanoma (KEYNOTE 002)
CLINICAL_TRIALS study record update · 2017-03-01
A Single Arm, Single-centre, Open-label, Exploratory Trial of Recombinant Interleukin-21 Administered Subcutaneously for 4 Weeks as Neo-adjuvant Treatment Prior to Sentinel Lymph Node/Complete Lymph Node Dissection Followed by 8 Weeks of Adjuvant Treatment in Subjects With Stage III Malignant Melanoma
CLINICAL_TRIALS study record update · 2017-02-23
Phase I Trial of Intratumoral pIL-12 Electroporation in Malignant Melanoma
CLINICAL_TRIALS study record update · 2017-02-08
Expanded Access Program With Nivolumab (BMS-936558) in Combination With Ipilimumab (Yervoy®) in Subjects With Unresectable or Metastatic Melanoma
CLINICAL_TRIALS study record update · 2016-12-07
A Phase I/II Trial of CDX-1401 (a Vaccine Consisting of a Human Monoclonal Antibody Specific for DEC-205, Fused to Full-length Tumor Antigen NY-ESO-1) in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients
CLINICAL_TRIALS study record update · 2016-11-17
Extension Protocol for Patients With Chronic Myelogenous Leukemia, Malignant Melanoma or Renal Cell Carcinoma That Have Responded to Treatment With Pegylated-Interferon α-2a or Roferon-A® in Prior Clinical Studies
CLINICAL_TRIALS study record update · 2016-11-02
A Phase I, Open-Label Study of the Safety and Pharmacokinetics of Escalating Doses of DEDN6526A in Patients With Metastatic or Unresectable Melanoma
CLINICAL_TRIALS study record update · 2016-10-25
Definition and Validation of an Immune Signature Predictive of Anti-PD1 Antibody Used Alone or an Association With antiCTLA4 in the Treatment of Advanced Melanoma : PREDIMEL
CLINICAL_TRIALS study record update · 2016-09-28
Randomized, Double-Blind, Placebo-Controlled Phase II Study Comparing the Safety of MDX-010 (BMS-734016) Administered With or Without Prophylactic Oral Budesonide (Entocort EC) in Patients With Previously Treated Unresectable Stage III or IV Malignant Melanoma
CLINICAL_TRIALS study record update · 2016-08-15
Phase I/II Trial of Vaccine Therapy With mRNA- Transfected Dendritic Cells in Patients With Advanced Malignant Melanoma
CLINICAL_TRIALS study record update · 2016-08-01
An Open-label, Single-arm, Phase II, Multicenter Study, to Evaluate the Efficacy of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
CLINICAL_TRIALS study record update · 2016-07-28
An Open-label, Multicenter, Single-arm, Phase I Dose-escalation With Efficacy Tail Extension Study of Vemurafenib (RO5185426) in Pediatric Patients With Surgically Incurable and Unresectable Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations
CLINICAL_TRIALS study record update · 2016-06-17
A Phase IB, Open-Label, Dose-Escalation Study Evaluating the Safety, Tolerability and Pharmacokinetics of Vemurafenib in Combination With GDC-0973 (Cobimetinib) When Administered in BRAFV600E Mutation-Positive Patients Previously Treated (But Without Prior Exposure to BRAF or MEK Inhibitor Therapy) or Previously Untreated for Locally Advanced/Unresectable or Metastatic Melanoma or Those Who Have Progressed After Treatment With Vemurafenib
CLINICAL_TRIALS study record update · 2016-06-09
A Dose Escalation Phase I Study of Radiotherapy Administered in Combination With Anti-CTLA4 Monoclonal Antibody (Ipilimumab) in Patients With Unresectable Stage III or Stage IV Advanced Malignant Melanoma
CLINICAL_TRIALS study record update · 2016-06-08
A Phase I Open-Label, Multicenter, Multiple-Dose Study to Investigate the Pharmacokinetics, Safety, and Efficacy of Vemurafenib in Chinese Patients With BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma
CLINICAL_TRIALS study record update · 2016-03-28
Evaluation of Concordance Between the Methods Used in INCa Platforms and the Cobas® 4800 BRAF V600 Mutation Test for Detection of BRAF V600 Mutations in Melanoma in Real Life Setting
CLINICAL_TRIALS study record update · 2016-03-02
Phase II Trial of Depsipeptide (NSC 630176) in Advanced Malignant Melanoma
CLINICAL_TRIALS study record update · 2016-02-17
Phase I/IIa AdCD40L Immunogene Therapy for Patients With Advanced Malignant Disease.
CLINICAL_TRIALS study record update · 2016-02-11
A SINGLE ARM, OPEN LABEL, EXPANDED ACCESS STUDY OF RG7204 IN PREVIOUSLY TREATED PATIENTS WITH METASTATIC MELANOMA
CLINICAL_TRIALS study record update · 2016-01-21
Phase II Study to Evaluate the Safety, Tolerability and Efficacy of CT-011 Administered Intravenously to Patients With Metastatic Melanoma